Growth Metrics

Neogenomics (NEO) Retained Earnings (2016 - 2026)

Neogenomics filings provide 17 years of Retained Earnings readings, the most recent being -$450.9 million for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 28.21% to -$450.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$450.9 million, a 28.21% decrease, with the full-year FY2025 number at $4000.0, up 101.94% from a year prior.
  • Retained Earnings hit -$450.9 million in Q1 2026 for Neogenomics, down from $4000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $4000.0 in Q4 2025 to a low of -$450.9 million in Q1 2026.
  • Median Retained Earnings over the past 5 years was -$189.9 million (2023), compared with a mean of -$176.1 million.
  • The widest YoY moves for Retained Earnings: up 101.94% in 2025, down 38725.44% in 2025.
  • Neogenomics' Retained Earnings stood at -$3.9 million in 2022, then tumbled by 6236.37% to -$247.1 million in 2023, then skyrocketed by 99.92% to -$206000.0 in 2024, then skyrocketed by 101.94% to $4000.0 in 2025, then tumbled by 11272900.0% to -$450.9 million in 2026.
  • The last three reported values for Retained Earnings were -$450.9 million (Q1 2026), $4000.0 (Q4 2025), and -$423.9 million (Q3 2025) per Business Quant data.